Pediatric IBD Foundation, ImproveCareNow, C-Path to Establish the Children’s Registry for the Advancement of Therapeutics TUCSON, Ariz., November 5, 2020 — The Pediatric IBD Foundation, ImproveCareNow, and the Critical Path Institute (C-Path)
FDA Awards C-Path Grant to Use Real-World Data to Generate Real-World Evidence in Neonates Pilot project will include the development of a Real-World Data and Analytics Platform TUCSON, Ariz., October 27, 2020 — Arizona
Rare Disease Cures Accelerator-Data and Analytics Platform First Year Milestones Highlighted at Virtual Workshop C-Path, NORD, FDA and more come together to showcase the importance of data sharing in rare disease drug development
C-Path Launches Consortium to Accelerate Medical Product Development in Sickle Cell Disease September is National Sickle Cell Awareness Month TUCSON, Ariz., Sept. 17, 2020 — The Critical Path Institute (C-Path) today
C-Path’s PSTC, D-RSC Receive Positive FDA Response for Drug-Induced Skeletal Muscle Injury Biomarkers Safety biomarkers aim to provide an additional tool for detecting acute drug-induced skeletal muscle injury in phase 1 clinical tr
C-Path’s PSTC, D-RSC Receive Positive FDA Response to Plan for Liver Safety Biomarker Biomarker aims to provide an additional tool for detecting the onset of hepatic injury in clinical trials involving patients with
C-Path Data Collaboration Center Analytics Team Wins Metadata Automation DREAM Challenge TUCSON, Ariz., July 14, 2020 — Tucson-based Critical Path Institute (C-Path) today proudly announced that the analytics team f
C-Path Launches CURE Drug Repurposing Collaboratory to Accelerate Identification of New Uses of Existing Drugs to Treat Infectious Diseases, Including COVID-19 Clinicians to report novel uses of existing drugs through FDA-NCATS CURE ID Mobile App. TUCSON, Ariz., June 23, 2020 — As millio
June 20, 2020 C-Path’s Transplant Therapeutics Consortium Receives Acceptance of Letter of Intent for iBox Scoring System (Composite Biomarker Panel) as a Reasonably Likely Surrogate Endpoint Biomarker aims to streamline the development of novel therapies intended to improve long-term outcomes for kidney transplan
C-Path and Provention Bio Announce Data Sharing Collaboration to Develop Advanced Drug Development Tools in Type 1 Diabetes TUCSON, Ariz., and OLDWICK, N.J. May 13, 2020 — The Critical Path Institute (C-Path) and Provention Bio, Inc. (Nas
